Marya D Zilberberg1, Brian H Nathanson2, Kate Sulham3, Andrew F Shorr4. 1. EviMed Research Group, LLC, PO Box 303, Goshen, MA, 01032, USA. evimedgroup@gmail.com. 2. OptiStatim, LLC, 25 Willow Circle, Longmeadow, MA, 01106, USA. 3. Spero Therapeutics, 675 Massachusetts Avenue, Cambridge, MA, 02139, USA. 4. Washington Hospital Center, 110 Irving Street NW, Washington, DC, 20010, USA.
Abstract
BACKGROUND: Complicated urinary tract infection (cUTI) is common among hospitalized patients. Though carbapenems are an effective treatment in the face of rising resistance, overuse drives carbapenem resistance (CR). We hypothesized that resistance to routinely used antimicrobials is common, and, despite frequent use of carbapenems, associated with an increased risk of inappropriate empiric treatment (IET), which in turn worsens clinical outcomes. METHODS: We conducted a retrospective cohort study of patients hospitalized with a culture-positive non-CR cUTI. Triple resistance (TR) was defined as resistance to > 3 of the following: 3rd generation cephalosporins, fluoroquinolones, trimethoprim-sulfamethoxazole, fosfomycin, and nitrofurantoin. Multivariable models quantified the impact of TR and inappropriate empiric therapy (IET) on mortality, hospital LOS, and costs. RESULTS: Among 23,331 patients with cUTI, 3040 (13.0%) had a TR pathogen. Compared to patients with non-TR, those with TR were more likely male (57.6% vs. 47.7%, p < 0.001), black (17.9% vs. 13.6%, p < 0.001), and in the South (46.3% vs. 41.5%, p < 0.001). Patients with TR had higher chronic (median [IQR] Charlson score 3 [2, 4] vs. 2 [1, 4], p < 0.001) and acute (mechanical ventilation 7.0% vs. 5.0%, p < 0.001; ICU admission 22.3% vs. 18.6%, p < 0.001) disease burden. Despite greater prevalence of empiric carbapenem exposure (43.3% vs. 16.2%, p < 0.001), patient with TR were also more likely to receive IET (19.6% vs. 5.4%, p < 0.001) than those with non-TR. Although mortality was similar between groups, TR added 0.38 (95% CI 0.18, 0.49) days to LOS, and $754 (95% CI $406, $1103) to hospital costs. Both TR and IET impacted the outcomes among cUTI patients whose UTI was not catheter-associated (CAUTI), but had no effect on outcomes in CAUTI. CONCLUSIONS: TR occurs in 1 in 8 patients hospitalized with cUTI. It is associated with an increase in the risk of IET exposure, as well as a modest attributable prolongation of LOS and increase in total costs, particularly in the setting of non-CAUTI.
BACKGROUND: Complicated urinary tract infection (cUTI) is common among hospitalized patients. Though carbapenems are an effective treatment in the face of rising resistance, overuse drives carbapenem resistance (CR). We hypothesized that resistance to routinely used antimicrobials is common, and, despite frequent use of carbapenems, associated with an increased risk of inappropriate empiric treatment (IET), which in turn worsens clinical outcomes. METHODS: We conducted a retrospective cohort study of patients hospitalized with a culture-positive non-CR cUTI. Triple resistance (TR) was defined as resistance to > 3 of the following: 3rd generation cephalosporins, fluoroquinolones, trimethoprim-sulfamethoxazole, fosfomycin, and nitrofurantoin. Multivariable models quantified the impact of TR and inappropriate empiric therapy (IET) on mortality, hospital LOS, and costs. RESULTS: Among 23,331 patients with cUTI, 3040 (13.0%) had a TR pathogen. Compared to patients with non-TR, those with TR were more likely male (57.6% vs. 47.7%, p < 0.001), black (17.9% vs. 13.6%, p < 0.001), and in the South (46.3% vs. 41.5%, p < 0.001). Patients with TR had higher chronic (median [IQR] Charlson score 3 [2, 4] vs. 2 [1, 4], p < 0.001) and acute (mechanical ventilation 7.0% vs. 5.0%, p < 0.001; ICU admission 22.3% vs. 18.6%, p < 0.001) disease burden. Despite greater prevalence of empiric carbapenem exposure (43.3% vs. 16.2%, p < 0.001), patient with TR were also more likely to receive IET (19.6% vs. 5.4%, p < 0.001) than those with non-TR. Although mortality was similar between groups, TR added 0.38 (95% CI 0.18, 0.49) days to LOS, and $754 (95% CI $406, $1103) to hospital costs. Both TR and IET impacted the outcomes among cUTI patients whose UTI was not catheter-associated (CAUTI), but had no effect on outcomes in CAUTI. CONCLUSIONS:TR occurs in 1 in 8 patients hospitalized with cUTI. It is associated with an increase in the risk of IET exposure, as well as a modest attributable prolongation of LOS and increase in total costs, particularly in the setting of non-CAUTI.
Authors: Andrew F Shorr; Scott T Micek; Emily C Welch; Joshua A Doherty; Richard M Reichley; Marin H Kollef Journal: Crit Care Med Date: 2011-01 Impact factor: 7.598
Authors: Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek Journal: Clin Infect Dis Date: 2016-07-14 Impact factor: 9.079
Authors: Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr Journal: Infect Control Hosp Epidemiol Date: 2018-07-31 Impact factor: 3.254
Authors: Tara Lagu; Mihaela S Stefan; Sarah Haessler; Thomas L Higgins; Michael B Rothberg; Brian H Nathanson; Nicholas S Hannon; Jay S Steingrub; Peter K Lindenauer Journal: J Hosp Med Date: 2014-04-09 Impact factor: 2.960
Authors: Marcos I Restrepo; Antonio Anzueto; Alejandro C Arroliga; Bekele Afessa; Mark J Atkinson; Ngoc J Ho; Regina Schinner; Ronald L Bracken; Marin H Kollef Journal: Infect Control Hosp Epidemiol Date: 2010-05 Impact factor: 3.254
Authors: Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin Journal: Infect Control Hosp Epidemiol Date: 2012-11-27 Impact factor: 3.254
Authors: David K Warren; Sunita J Shukla; Margaret A Olsen; Marin H Kollef; Christopher S Hollenbeak; Michael J Cox; Max M Cohen; Victoria J Fraser Journal: Crit Care Med Date: 2003-05 Impact factor: 7.598
Authors: Scott T Micek; Katherine E Kollef; Richard M Reichley; Nareg Roubinian; Marin H Kollef Journal: Antimicrob Agents Chemother Date: 2007-08-06 Impact factor: 5.191
Authors: Marya D Zilberberg; Brian H Nathanson; Shamil Sadigov; Thomas L Higgins; Marin H Kollef; Andrew F Shorr Journal: Chest Date: 2009-05-22 Impact factor: 9.410
Authors: Michael B Rothberg; Penelope S Pekow; Aruna Priya; Marya D Zilberberg; Raquel Belforti; Daniel Skiest; Tara Lagu; Thomas L Higgins; Peter K Lindenauer Journal: PLoS One Date: 2014-01-31 Impact factor: 3.240